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Abstract
Introduction Rho signaling regulates key cellular processes
including proliferation, survival, and migration, and it has been
implicated in the development of many types of cancer including
breast cancer. P190B Rho GTPase activating protein
(RhoGAP) functions as a major inhibitor of the Rho GTPases.
P190B is required for mammary gland morphogenesis, and
overexpression of p190B in the mammary gland induces
hyperplastic lesions. Hence, we hypothesized that p190B may
play a pivotal role in mammary tumorigenesis.
Methods To investigate the effects of loss of p190B function on
mammary tumor progression, p190B heterozygous mice were
crossed with an MMTV-Neu breast cancer model. Effects of
p190B deficiency on tumor latency, multiplicity, growth,
preneoplastic progression and metastasis were evaluated. To
investigate potential differences in tumor angiogenesis between
the two groups, immunohistochemistry to detect von Willebrand
factor was performed and quantified. To examine gene
expression of potential mediators of the angiogenic switch, an
angiogenesis PCR array was utilized and results were confirmed
using immunohistochemistry. Finally, reciprocal transplantation
of tumor fragments was performed to determine the impact of
stromal deficiency of p190B on tumor angiogenesis.
Results P190B deficiency reduced tumor penetrance (53% of
p190B+/-Neu mice vs. 100% of p190B+/+Neu mice formed
tumors) and markedly delayed tumor onset by an average of 46
weeks. Tumor multiplicity was also decreased, but an increase
in the number of preneoplastic lesions was detected indicating
that p190B deficiency inhibited preneoplastic progression.
Angiogenesis was decreased in the p190B heterozygous
tumors, and expression of a potent angiogenic inhibitor,
thrombospondin-1, was elevated in p190B+/-Neu mammary
glands. Transplantation of p190B+/-Neu tumor fragments into
wild-type recipients restored tumor angiogenesis. Strikingly,
p190B+/+Neu tumor fragments were unable to grow when
transplanted into p190B+/-Neu recipients.
Conclusions These data suggest that p190B
haploinsufficiency in the epithelium inhibits MMTV-Neu tumor
initiation. Furthermore, p190B deficiency in the vasculature is
responsible, in part, for the inhibition of MMTV-Neu tumor
progression.
Introduction
Small GTPases of the Rho family act as nodes of signal trans-
duction, integrating extracellular signals to affect actin
cytoskeletal organization, cell adhesion, polarity, proliferation
and migration, which are all important processes that become
deregulated during cancer progression. Rho proteins are
molecular switches that cycle between an active GTP-bound
state and an inactive GDP-bound state, and their activities are
spatially and temporally regulated. Three classes of proteins
control Rho activity, including guanine nucleotide exchange
BSA: bovine serum albumin; GAP: GTPase activating protein; GTPases: guanine nucleotide triphosphatases; MMTV: mouse mammary tumor virus; 
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factors that activate the switch, GTPase activating proteins
(GAPs) that inactivate the switch, and guanine nucleotide dis-
sociation inhibitors that prevent the exchange of GDP for GTP
on the endogenous RhoGTPases [1-3]. Several studies have
shown overexpression of Rho family members in human breast
cancer samples by immunohistochemistry, by mutational anal-
ysis, or by RNA expression profiling [4-7]. The role of Rho sig-
naling in breast cancer, however, is not well understood.
To elucidate the contribution of the Rho signaling pathway to
the growth and progression of breast cancer, we focused on
understanding the role of p190B RhoGAP, which has been
shown previously to play an important role in normal mammary
gland development [8,9]. P190B is a member of the RhoGAP
family, which acts as negative regulator of Rho activity. The
GAP domain of p190B demonstrated activity against Rho,
Rac and Cdc42 [10], and more recently p190B was shown to
directly bind Rnd3, Rac1 and RhoA [11]. Homozygous dele-
tion of p190B results in central nervous system and lung
defects, leading to perinatal lethality [12]. P190B-deficient
embryos and cells are smaller than their wild-type counter-
parts, due in part to impaired insulin-like growth factor signal-
ing. Importantly, the p190B and insulin-like growth factor
signaling pathways have been shown to directly interact
through Rho kinase (ROK) phosphorylation of insulin receptor
substrate proteins and to be critically involved in regulating
both cell growth and differentiation [12,13].
P190B is highly expressed throughout embryonic and virgin
mammary gland development, with expression decreasing
during late pregnancy and remaining low during lactation
[14,15]. P190B homozygous-deficient mammary glands fail to
undergo ductal morphogenesis. Moreover, loss of one allele of
p190B transiently delays ductal morphogenesis and results in
decreased proliferation within the terminal end buds, which
drive ductal penetration into the fat pad [8]. Overexpression of
p190B during virgin development disrupts terminal end bud
morphogenesis, increases side branching, and delays ductal
elongation, while overexpression during pregnancy results in
hyperplastic lesions [9].
To elucidate the role of p190B in mammary tumor progression,
we crossed p190B heterozygous mice with a mouse mam-
mary tumor virus (MMTV)-Neu mouse model of breast cancer
and examined multiple stages of tumor progression. Neu/
ErbB2 is a member of the epidermal growth factor receptor
family that is amplified and overexpressed in 20 to 30% of
human breast cancers and correlates with poor prognosis
[16]. Several mouse models have been generated to examine
mechanisms involved in ErbB2-mediated mammary tumor pro-
gression [17]. For these studies, we chose to use the MMTV-
Neu model that overexpresses a wild-type Neu proto-onco-
gene [18]. MMTV-Neu female mice develop preneoplastic
lesions, some of which progress to adenocarcinomas, with a
median onset of 7 months of age. Approximately 70 to 80% of
tumor-bearing mice develop metastasic disease [18]. GAPs
and related G proteins are reportedly upregulated in these
tumors, suggesting that Rho signaling is important for MMTV-
Neu tumor formation and progression [19].
Using this approach, we demonstrate that p190B plays a crit-
ical role in MMTV-Neu-induced tumorigenesis. Strikingly, loss
of one allele of p190B decreased tumor penetrance, delayed
tumor onset, and reduced metastasis. Furthermore, the pro-
gression of preneoplastic lesions was inhibited by the loss of
p190B, and p190B heterozygous tumors have a reduced vas-
cular network, thus implicating p190B in tumor angiogenesis.
Reciprocal transplantation of tumor fragments confirmed that
p190B expression in the stroma plays an important role in
tumor angiogenesis. The effects of p190B loss on angiogen-
esis may be due in part to increased expression of a potent
anti-angiogenic factor, thrombospondin-1 (TBS-1). The reduc-
tion in angiogenesis may contribute to the inhibition of metas-
tasis.
Materials and methods
Mice strains and tumor analysis
P190B null mice [12] were backcrossed to FVB for four gen-
erations. P190B+/- (FVB4) mice were then crossed to MMTV-
Neu transgenic mice, a fifth cross to FVB, to yield control and
experimental animals. Mice were fed a conventional diet ad
libitum and were maintained at 21 to 22°C with a 12-hour light
and 12-hour dark cycle.
Animal protocols were approved by the Animal Care and Use
Committee of Baylor College of Medicine, and were con-
ducted in accordance with the provisions of the Guide for the
Care and Use of Laboratory Animals and the Animal Welfare
Act.
Mice were monitored weekly by palpation for tumor induction.
Individual tumor size and location was recorded. Twenty
p190B+/+/MMTV-Neu littermates and 15 p190B+/-/MMTV-
Neu littermates were analyzed, and Kaplan-Meier analysis was
performed to determine tumor-free survival. Log-rank test anal-
ysis was performed to determine whether differences between
the two groups were statistically significant.
Tissue preparation
Heterozygous females (p190B+/- FVB5:C57Bl/6) were mated
with heterozygous males (MMTV-Neu FVB), with detection of
tumors taking place in the F1 generation. Mice at tumor bur-
den (1.0 mm3) were given an intraperitoneal injection of bro-
modeoxyuridine (100 mg/kg). Two hours later, the tumors,
mammary glands, and lungs were dissected and fixed for 2
hours in 4% paraformaldehyde. Tumor and lung specimens
were dehydrated and embedded in paraffin. Gland specimens
were defatted with acetone and stained with Neutral Red over-
night, followed by clearing with xylene [20]. Whole-mount pic-
tures were taken using a stereomicroscope (Leica,Available online http://breast-cancer-research.com/content/11/4/R61
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Bannockburn, IL, USA; Model M165 C). After imaging, whole-
mounted mammary glands were paraffin embedded. Five-
micrometer serial sections were cut into the frontal plane for
subsequent histological and immunostaining analysis.
Preparation of tumor lysates and western 
blotting
Protein lysates were prepared as previously described [9].
Protein concentrations in the tissue extracts, p190B+/+Neu (n
= 5) or p190B+/-Neu (n = 5), were determined using the BCA
Protein Quantitation Assay (Pierce, Rockford, IL, USA).
Extracts were pooled (20 μg of each), electrophoresed on 6%
or 12% SDS-PAGE gels, and transferred to polyvinylidene flu-
oride (PVDF) membrane (Millipore, Bedford, MA, USA). Mem-
branes were blocked in 5% milk/Tris-buffered saline Tween-
20 followed by incubation with p190B 1:1,000 antibody (BD
Bioscience, San Jose, CA, USA), ErbB2/Neu 1:1,000 (Neo-
markers, Fremont, CA, USA), ErbB3 1:1,000 (Santa Cruz,
Santa Cruz, CA, USA), ERK 1:1,000 (Cell Signaling, Danvers,
MA, USA), phospho-p21-activated kinase (PAK)1/2 1:1,000
(Cell Signaling), and β-actin 1:5,000 (Sigma, St Louis MO,
USA) in 5% milk/Tris-buffered saline Tween-20. Other west-
ern blot assays were completed and developed as previously
described [9].
Immunohistochemistry and quantification of 
staining
Immunohistochemistry was carried out as previously reported
[9] using cleaved caspase 3 (9961; Cell Signaling), 1:200 in
5% BSA, 0.5% blocking buffer; biotin-conjugated bromodeox-
yuridine (550803; BD Pharmingen), 1:10 in 5% BSA, 0.5%
blocking buffer; and TBS-1 (NeoMarkers), 1:75 in MOM block
(Vector Laboratories, Burlingame, CA, USA). Immunofluores-
cence for von Willebrand factor (VWF) was performed
according to the manufacturer's protocol using anti-VWF
(DAKO, Glostrup Denmark), 1:200 in 5% BSA, 0.5% blocking
buffer.
Two independent observers blinded to the experimental
groups assessed the peritumoral vascular density by counting
the number of vessels within three 100× fields from each sam-
ple. Quantification of TBS-1 staining was performed by count-
ing the number of TBS-1-positive cells in five fields from one
gland from each of five mice per genotype.
RNA extraction and quantitative real-time PCR
RNA was isolated from briefly digested (collagenase 2 mg/ml
for 1 hour) mammary glands to remove adipose tissue of
p190B+/+Neu and p190B+/-Neu adult virgin mice according
to the manufacturer's protocol (SABiosciences, Frederick,
MD, USA). Briefly, Trizol (Invitrogen, Carlsbad, CA, USA) solu-
tion was used to according to the manufacturer's protocol fol-
lowed by an additional purification step using the RNA easy kit
(Qiagen, Germantown, MD, USA). The expression of mRNAs
involved in the angiogenesis pathway was determined using
real-time PCR and a SuperArray Profiler PCR array (SABio-
sciences, Frederick, MD, USA).
For quantification, cDNA was synthesized using 1 μg RNA in
a reverse transcription reaction (SABiosciences). cDNA was
amplified using the SYBR Green qPCR Master Mix (SABio-
sciences) with a real-time PCR Applied Biosystems 7500
thermocycler (Applied Biosystems Inc, Foster City, CA, USA).
Samples were run in triplicate.
Manufacturer-supplied primer pairs were used to measure
mRNAs expressed in the angiogenesis pathway (PAMM-024;
SABiosciences) as described in the manufacturer's protocol.
The mRNA expression levels were normalized to the expres-
sion level of 4/5 housekeeping genes included in the array,
excluding  β-actin. The positive threshold was determined
based on negative controls as described in the manufacturer's
protocol. The calculations for determining relative gene
expression were made using the cycle threshold method and
web-based PCR array data analysis (SABiosciences).
GTPase activity assays
Activities of Rho family GTPases were measured using lumi-
nescent (RhoA and Rac1) or colorimetric (Cdc42) G-LISA
assays (Cytoskeleton, Denver, CO, USA) according to the
manufacturer's instructions. Frozen tumors were pulverized
using a mortar and pestle, and were homogenized in lysis
buffer containing protease inhibitors (Cytoskeleton) using a
needle and syringe. The lysates were centrifuged for 2 minutes
at 4°C and 14,000 × g, and the clarified lysates were aliq-
uoted, snap-frozen in liquid nitrogen, and stored at -80°C.
The protein concentration was determined using the protein
assay reagent provided. Immediately before the assays, the
lysates were thawed and the protein concentrations were
equalized (0.75 mg/ml for RhoA and Rac1, 2.0 mg/ml for
Cdc42) using lysis buffer. For the luminescent assays, Super-
Signal West Dura chemiluminescent substrate (Thermo Sci-
entific, Rockford, IL, USA) was substituted for the kit
substrate, and a Kodak Gel Logic 1500 digital imaging system
and Kodak 1D software (Carestream Health, New Haven, CT,
USA) were used to determine the luminescent intensity. For
the colorimetric assay, a SpectraMax Plus 384 spectropho-
tometer and SoftMax Pro software (Molecular Devices, Sunny-
vale, CA, USA) were used to determine the absorbance.
Means were compared using a t test in GraphPad Prism soft-
ware (GraphPad Software, Inc., La Jolla, CA, USA).
Mammary tumor tissue transplantation
Three week-old SCID/Beige mice (Charles River, German-
town, MD, USA) were employed as hosts for transplantation.
Both of the Number 4 inguinal mammary glands were cleared
of endogenous epithelium. A single tumor piece (1 mm3 in
size) was implanted into an incision made in the cleared fat
pad of the recipient gland. Mice were monitored weekly by pal-Breast Cancer Research    Vol 11 No 4    Heckman-Stoddard et al.
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pation for tumor induction. The individual tumor size was
recorded. Mice were euthanized when tumors reached 10
mm3 in size and were analyzed as described above. For these
studies, fragments from five tumors per genotype were each
transplanted into 40 recipients. A Fisher's exact test was used
to evaluate whether there was a statistically significant differ-
ence in transplantation take rates between the two groups.
For reciprocal transplants, 5-week old p190B+/+Neu mice and
p190B+/-Neu mice were employed as hosts for transplanta-
tions. Both of the Number 4 glands were cleared of endog-
enous epithelium. A single tumor piece (1 mm3 in size) was
implanted into an incision made in the cleared fat pads of the
recipient gland. Mice were monitored weekly by palpation for
tumor induction, and the individual tumor size was recorded.
Mice were euthanized when the total tumor burden reached
15 mm3 in size and were analyzed as described above. For
these studies, fragments from three tumors per genotype were
transplanted into both Number 4 cleared glands of three recip-
ient mice.
Results
Haploinsufficiency for p190B inhibits MMTV-Neu 
tumorigenesis
To examine whether p190B haploinsufficiency affects mam-
mary tumorigenesis, we first backcrossed p190B hetero-
zygous mice (C57Bl/6) into the FVB background to
circumvent effects of strain-specific modifiers present in the
C57Bl/6 background that have been reported to delay mam-
mary tumorigenesis [21]. We previously reported that p190B
heterozygosity resulted in a transient delay in mammary gland
development between 4 and 6 weeks of age, but that subse-
quent mammary gland development and function was unaf-
fected [8]. P190B heterozygous mice (C57Bl/6/FVB5) were
then crossed with MMTV-Neu transgenic mice [18] to ascer-
tain whether haploinsufficiency of p190B would have any
effect on tumor initiation, progression and/or metastasis. The
virgin offspring from these crosses were monitored by weekly
palpation beginning at 3 months of age and were followed for
18 months.
Strikingly, p190B+/-Neu mice developed tumors with a mark-
edly increased latency compared with the MMTV-Neu mice
(74 weeks vs. 35 weeks, P < 0.0001; Figure 1a), In addition,
p190B haploinsufficiency significantly reduced tumor pene-
trance, in that 53% (8/15) of the heterozygous mice had pal-
pable tumors as compared with 100% (20/20) of the MMTV-
Neu wild-type mice (P < 0.001). Immunoblotting using tumor
extracts confirmed that the levels of p190B were lower in the
p190B+/-Neu tumors, as expected (Figure 1b). Haploinsuffi-
ciency for p190B also decreased tumor multiplicity (Figure
1c). To determine whether ErbB2 signaling was changed in
the p190B+/-Neu tumors, we examined the levels of ErbB2/
Neu and ErbB3; these levels were similar between the
p190B+/+Neu and p190B+/-Neu tumors (Figure 1d).
P190B+/+Neu and p190B+/-Neu tumors have similar 
histology and growth, but differential signaling
Histological examination showed that, similar to wild-type
MMTV-Neu mice, p190B+/-Neu mice formed adenocarcino-
mas with grossly similar histopathologies. There appeared to
be, however, fewer large blood vessels in the p190B hetero-
zygous tumors as compared with the wild-type tumors (Figure
2a). The p190B+/+Neu and p190B+/-Neu tumors had similar
growth patterns after initial palpation (Figure 2b). Examination
of bromodeoxyuridine incorporation and cleaved caspase 3 as
markers of S-phase and apoptosis, respectively, revealed no
differences between the p190B+/-Neu tumors and the
p190B+/+Neu tumors (data not shown).
Western blot analysis of downstream effectors of Rho, how-
ever, revealed that p190B+/+Neu tumors had remarkably dif-
ferent Rho signaling patterns as compared with the p190B+/-
Neu tumors (Figure 2c). While p190B+/+Neu tumors had very
little tumor-to-tumor variation, the p190B+/-Neu tumors exhib-
ited variable expression of several of the downstream signaling
molecules. One notable exception was that a consistent
decrease in phosphorylated ROK was detected in the
p190B+/-Neu tumors. Some of the heterozygous tumors also
exhibited a decrease in total ROK. Interestingly, the levels of
PAK1/2 were elevated in the p190B+/-Neu tumors. We also
examined the levels of active Rac1, RhoA, and Cdc42. Rac1
was significantly decreased in the heterozygous tumors while
RhoA and Cdc42 were unaltered (Figure 2d). These data
show that heterozygosity for p190B does not affect tumor his-
tology or growth, but does affect Rho signaling pathways.
Haploinsufficiency for p190B blocks preneoplastic 
progression by reducing angiogenesis
To determine how p190B haploinsufficiency was inhibiting
tumor progression we examined using whole-mount analysis
the remaining mammary glands from mice that had developed
tumors. These glands exhibited many abnormalities, including
enlarged ducts, alveolar-like development, and preneoplastic
lesions (Figure 3a). The number of preneoplastic lesions in
one number 4 inguinal gland from each mouse at the time of
sacrifice for tumor burden was quantified. This analysis
revealed that the p190B+/-Neu mice had threefold more
lesions than the p190B+/+Neu mice (Figure 3b). The p190B+/
+Neu lesions were more proliferative than the p190B+/-Neu
lesions by bromodeoxyuridine incorporation, but no differ-
ences in apoptosis were detected (data not shown).
Angiogenesis is a key step in the progression of preneoplastic
lesions (1 to 2 mm in size) to overt tumors [22]. We therefore
considered the possibility that a block in the angiogenic switch
may be one potential mechanism by which haploinsufficiency
for p190B resulted in an increased number of preneoplastic
lesions, but fewer tumors. To examine the gene expression of
potential mediators of the angiogenic switch, mRNA isolated
from 8-week-old to 12-week-old p190B+/-Neu and p190B+/-Available online http://breast-cancer-research.com/content/11/4/R61
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Neu virgin mammary glands was analyzed using an angiogen-
esis Superarray platform. While few significant changes in
expression of these genes were detected, we observed a two-
fold increase in the mRNA expression of TBS-1 (Figure 3c and
Additional data file 1), a potent angiogenic inhibitor produced
by stromal fibroblasts, endothelial cells and immune cells. Fur-
thermore, quantification of immunostaining to detect TBS-1
protein in mammary gland sections demonstrated that expres-
sion of TBS-1 was elevated twofold in the p190-B+/-Neu
glands as compared with the wild-type glands (Figure 3d, e).
These data suggest that p190B haploinsufficiency delays pre-
neoplastic progression through inhibition of the angiogenic
switch.
Loss of p190B results in decreased tumor vasculature 
and fewer lung metastases
To determine whether this inhibition of angiogenesis is also
present in p190B+/-Neu tumors, we assessed the number of
vessels using immunostaining for an endothelial specific
marker (VWF) (Figure 4b). This analysis showed a twofold
decrease in the number of vessels in the p190B+/-Neu tumors
as compared with the p190B+/+Neu tumors (Figure 4a). We
also examined the lungs of p190B+/-Neu and p190B+/+Neu
mice with similar tumor burdens to determine whether p190B
haploinsufficiency affected metastasis. The percentage of
mice with metastases was not significantly different between
the two genotypes due to the limited number of p190B heter-
ozygous mice that exhibited primary tumors. The p190B+/-Neu
mice developed fewer metastatic nodules than the p190B+/
+Neu mice, however, despite the fact that they had similar pri-
mary tumor burdens (Figure 4c). These results suggest that
haploinsufficiency for p190B inhibits tumor angiogenesis and
ensuing metastatic progression of the p190B+/-Neu tumors.
Figure 1
Haploinsufficiency for p190B delays MMTV-Neu tumor onset and causes a decrease in tumor multiplicity Haploinsufficiency for p190B delays MMTV-Neu tumor onset and causes a decrease in tumor multiplicity. (a) Kaplan-Meier tumor-free survival curve 
of p190B+/+Neu mice and p190B+/-Neu mice. The median time of tumor-free survival was 251 days and 591 days, respectively. Log-rank test anal-
ysis showed a significant difference between the two groups (P < 0.0001). (b) Immunoblotting for p190B and ERK in pooled tumor tissue from five 
tumors of indicated genotypes. (c) Tumor multiplicity for p190B+/+Neu mice and for p190B+/-Neu mice (1.8 and 1.2 tumors per mouse, respec-
tively). Student's t test showed a significant decrease (P < 0.04). (d) Immunoblotting for ErbB2, ErbB3, and β-actin in six individual tumors from the 
indicated genotypes. Error bars, standard error of the mean.Breast Cancer Research    Vol 11 No 4    Heckman-Stoddard et al.
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Angiogenesis defect in p190B+/-Neu tumors is rescued 
by wild-type stroma and growth of wild-type tumors is 
inhibited by heterozygous stroma
To determine the relative contribution of the epithelium and the
stroma to the tumor progression process, tumor pieces from
p190B+/+Neu tumors and from p190B+/-Neu tumors were
transplanted into cleared fatpads of SCID/beige mice. Inter-
estingly, the p190B+/-Neu tumor transplants grew faster than
the p190B+/+Neu tumors, with a mean time to tumor burden
of 89 days compared with 126 days, respectively (P  <
0.0001; Figure 5a). The transplantation take rates were similar
between the two groups (Figure 5b), with no statistical differ-
ence determined by the Fisher exact test.
We next analyzed the transplanted tumors to determine
whether the vascular defect seen in the original tumors per-
sisted in the transplants. For this analysis, the tumors were
stained with VWF and the vessels were counted. Interestingly,
no significant differences in the number of large and small ves-
sels were observed in both the p190B+/+Neu and p190B+/-
Neu tumor transplants (Figure 5c, d). These data indicate that
the effects of p190B haploinsufficiency on MMTV-Neu tumor
Figure 2
P190B+/+Neu tumors and p190B+/-Neu tumors have similar histology and growth, but differential signaling P190B+/+Neu tumors and p190B+/-Neu tumors have similar histology and growth, but differential signaling. (a) Histological section of p190B+/+Neu 
tumors and p190B+/-Neu tumors stained with hematoxylin and eosin (H&E). Arrows point to vasculature. Scale bar = 50 μm. (b) Growth curve of 
p190B+/+Neu tumors and p190B+/-Neu tumors. No statistical difference. (c) Immunoblotting for phosphorylated Rho kinase (pROK), Rho kinase 
(ROK), phosphorylated p21-activated kinase (p-PAK)1/2, and total ERK and actin as loading controls in four independent tumors from each indi-
cated genotype. Quantification of western blots is graphed. (d) Quantification of active GTPase levels in tumor tissue. Analysis was carried out using 
Image J software. Error bars, standard error of the mean.Available online http://breast-cancer-research.com/content/11/4/R61
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angiogenesis are due to defects in the vasculature and/or
stroma.
Finally, we performed reciprocal transplants using p190B+/
+Neu and p190B+/-Neu 5-week-old mice as the host to exam-
ine the contribution of the heterozygous stroma. The p190B+/
-Neu tumor pieces all grew to form tumors in the p190B+/+Neu
stroma (n = 6), while none of the p190B+/+Neu tumor pieces
grew to form tumors in the presence of the p190B+/-Neu
stroma (n = 6). These data further support p190B haploinsuf-
ficiency in the vasculature and/or stroma as being responsible
for the tumor growth potential.
Discussion
In the present article we show that p190B RhoGAP, a gene
that is essential for mammary gland development, plays a crit-
ical role in MMTV-Neu mammary tumor progression. Haploin-
sufficiency for p190B increases tumor-free survival, reduces
Figure 3
Haploinsufficiency for p190B blocks preneoplastic progression by reducing angiogenesis Haploinsufficiency for p190B blocks preneoplastic progression by reducing angiogenesis. (a) Mammary tissues from tumor burden mice with the 
indicated genotypes were examined by whole-mount analyses. Arrows, preneoplasias detected. LN, lymph node. Scale bar = 500 μm. (b) Number 
of preneoplastic lesions in one Number 4 inguinal gland per tumor-burden mouse was quantified. Student's t test showed significant difference 
between groups (P < 0.04). (c) Gene expression qRT-PCR data from Superarray angiogenesis array. Array analysis revealed a twofold increase in 
thrombospondin-1 (TBS-1) in the p190B+/-Neu mammary glands of adult mice 8 to 12 weeks of age. (d) Immunohistochemistry to detect TBS-1 
protein demonstrated that TBS-1 expression is localized to the mammary epithelium and is increased in p190B+/-Neu mammary glands (upper) as 
compared with wild-type glands (lower). Images shown are at 400× magnification. (e) Quantification of TBS-1 immunostaining showed that TBS-1 
protein is increased fourfold in p190B+/-Neu mammary glands. Error bars, standard error of the mean.Breast Cancer Research    Vol 11 No 4    Heckman-Stoddard et al.
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tumor penetrance, and decreases tumor multiplicity. The level
of Neu transgene expression is unaltered in the p190B+/-Neu
normal mammary tissue and tumors, and thus downregulation
of transgene expression is not responsible for the inhibition of
tumor progression. ErbB3 expression was also similar
between the two groups, suggesting that p190B deficiency
does not inhibit Neu-induced tumorigenesis by altering the
epidermal growth factor receptor signaling axis that promotes
tumor formation in this model [23]. Interestingly, p190B heter-
ozygosity does not inhibit the growth rate of established
tumors. Furthermore, we found in a few of the p190B+/-Neu
tumors that p190B expression levels were comparable with
the levels detected in the p190B+/+Neu tumors (data not
shown).
It has been reported that GAPs and related G proteins are
upregulated in MMTV-Neu tumors [19], and our results con-
firm that this signaling network plays an important role in
MMTV-Neu tumor progression. Based on previous studies
using p190B-deficient mouse embryonic fibroblasts [12], we
anticipated that reduced p190B expression in vivo would
increase Rho GTPase activities as well as signaling through
the downstream effectors ROK and PAK. GTPase assays to
examine the levels of active RhoA, Rac1, and Cdc42, however,
demonstrated that only Rac1 levels were altered in the heter-
ozygous tumors, and they were in fact decreased. In addition,
ROK activity - and in some cases ROK expression levels -
were reduced in the p190B-deficient tumors, whereas PAK1/
2 activity levels were increased. These data indicate that
p190B is required for proper regulation of Rho/ROK signaling
during Neu mammary tumor progression.
Rac1 and PAK activities have been shown to play important
roles in mammary tumorigenesis [24,25], and thus PAK1/2
activities may be elevated in the p190B-deficient mice to com-
pensate for the decrease in Rac1 activity. It is interesting, and
perhaps not surprising, that p190B deficiency does not result
in persistent upregulation of Rho GTPase activity in the
tumors. Rho GTPases play critical roles in essential cellular
processes such as cell cycle progression, mitosis, and cell
survival, and GTPase activity is tightly controlled during these
processes [26]. Downstream effectors such as PAK and ROK
are also critical for these processes [27,28]. A loss of p190B
resulting in persistently elevated activity of several Rho
Figure 4
Loss of p190B results in decreased tumor vasculature and fewer lung metastases Loss of p190B results in decreased tumor vasculature and fewer lung metastases. (a) Number of vessels per 100× section of tumor stained with 
von Willebrand factor (VWF) was quantified. Student's t test shows a significant difference between groups (P < 0.0001). (b) Representative pic-
tures of VWF immunofluorescence (red) and dapi (blue) in the two different genotypes as indicated. Arrows mark blood vessels. Scale bar = 100 
μm. (c) Number of metastases per mouse at tumor burden, as determined by counting metastatic nodules in serial sections of the entire lung. Stu-
dent's t test showed a significant decrease in p190B+/-Neu tumor mice (P < 0.03). Error bars, standard error of the mean.Available online http://breast-cancer-research.com/content/11/4/R61
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GTPases is therefore likely to have a negative impact on cell
survival or proliferation. Other GAPs or guanine nucleotide dis-
sociation inhibitors may be upregulated or the guanine nucle-
otide exchange factor activity may be downregulated to
compensate for the loss of p190B. In some tumors, we noted
that p190B levels were similar to levels in wild-type tumors,
suggesting compensatory mechanisms were functioning to
restore p190B levels.
Figure 5
Angiogenesis defect in p190B+/-Neu tumors is rescued by wild-type stroma Angiogenesis defect in p190B+/-Neu tumors is rescued by wild-type stroma. (a) Number of days to tumor burden following transplantation of a des-
ignated genotype tumor piece into the cleared fatpad of a SCID/Beige mouse. Decreased time to tumor burden was statistically significant in 
p190B+/-Neu tumor transplants. (b) Percentage take rate of p190B+/+Neu transplants and p190B+/-Neu transplants. No statistical difference was 
seen between genotypes. (c) Number of vessels per 100× section of tumor stained with von Willebrand factor (VWF) was quantified. No statistical 
difference between genotypes was detected. (d) Representative pictures of VWF immunofluorescence (red) and dapi (blue) in the two different 
genotypes as indicated. Arrows mark blood vessels. Scale bar = 100 μm. (e) Percentage take rate of p190B+/-Neu tumors into a p190B+/+Neu host 
and of p190B+/+Neu tumors into a p190B+/-Neu host. The p190B+/-Neu tumors had a 100% take rate, while the p190B+/+Neu tumors had a 0% 
take rate. Statistically significant difference P < 0.0001. Error bars, standard error of the mean.Breast Cancer Research    Vol 11 No 4    Heckman-Stoddard et al.
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Taken together, these results demonstrate that p190B defi-
ciency results in unexpected effects on the Rho signaling axis
and reveal an important role for p190B in regulating these sig-
naling pathways during mammary tumor progression. In addi-
tion, these results highlight the importance of investigating the
role of these signaling pathways in tumorigenesis in the con-
text of the complex in vivo environment.
Examination of the mammary glands from the p190B+/-Neu
tumor-burden mice indicated that there were a higher number
of preneoplastic lesions. This increase probably resulted from
a lack of progression, since averaging the number of preneo-
plastic lesions and the number of tumors showed no statistical
difference in the total number of initiated lesions between the
p190B+/+Neu mice and the p190B+/-Neu mice. These prene-
oplastic lesions were characteristic of the avascular phase of
the angiogenic switch, as they were approximately 1 to 2 mm
in diameter [22,29]. Interestingly, several p190B+/-Neu mice
did not develop tumors by 18 months of age and, when their
glands were examined for preneoplastic lesions, no lesions
were detected (7/7 mice) (data not shown). These data sug-
gest that p190B is important for the progression of preneo-
plastic lesions, but that it may also play a role in tumor initiation.
Further studies in which normal mammary tissue pieces from
p190B+/-Neu mice are transplanted into wild-type stroma and
are allowed to proceed through the stochastic process of
tumor formation will be required to examine preneoplastic
lesions in more detail.
The possibility that p190B was important for the progression
of avascular preneoplastic lesions to vascularized lesions
prompted us to examine angiogenesis in the p190B+/-Neu
mice. To characterize the potential for a vascular defect in
these mice we utilized the Superarray qRT-PCR angiogenesis
platform, which allowed us to examine the expression of 87
angiogenesis genes, both positive and negative regulators,
including vascular endothelial growth factor, matrix metallopro-
teinase-2 and matrix metalloproteinase-9, hypoxia inducible
factor 1 alpha, fibroblast growth factor genes, TBS-1, and
transforming growth factor beta genes. Only TBS-1 was sig-
nificantly increased within the adult virgin mammary glands of
the p190B+/-Neu mice, and quantification of immunostaining
for TBS-1 confirmed this increase.
Previous studies have demonstrated that TBS-1 is a compo-
nent of the extracellular matrix that functions as a negative reg-
ulator of tumor vasculature, and TBS-1 expression
dramatically effects mammary tumorigenesis. For example,
overexpression of TBS-1 inhibited angiogenesis in transgenic
mice overexpressing activated Neu, resulting in delayed tumor
onset and reduced tumor penetrance [30]. Conversely, TBS-
1 deficiency in the transgenic mice overexpressing activated
Neu increased angiogenesis, enhanced growth, and reduced
tumor latency [30].
TBS-1 has previously been linked to GTPase signaling. Ras/
Rho signaling has been shown to repress TBS-1 through
effects on phosphatidyl inositol-3 kinase [31], and Ras/Rho-
mediated suppression of TBS-1 has been suggested as nec-
essary to promote angiogenesis [32]. Disruption of Rho/ROK
signaling may therefore account for the elevated TBS-1
expression that was detected in the p190B+/-Neu mice.
Increased expression of this potent angiogenic inhibitor may
be responsible, in part, for the dramatic inhibition of tumorigen-
esis that occurred in the p190B+/-Neu mice.
Consistent with the increased TBS-1 expression in p190B+/-
Neu mammary glands, p190B haploinsufficiency also resulted
in decreased angiogenesis in the tumors. This persistent vas-
cular defect may be responsible for the decreased number of
metastatic nodules detected in the tumor-bearing p190B het-
erozygous mice. Interestingly, an increased vascular density
has been correlated with poor breast cancer prognosis, and
TBS-1 expression was inversely correlated with malignant pro-
gression of mammary and lung carcinomas as well as
melanoma [33,34].
Our transplantation experiments showed that the reduction in
angiogenesis was probably due to defects in the stroma or
vasculature because transplantation of p190B+/-Neu tumor
pieces into wild-type stroma restored angiogenesis to the lev-
els detected in wild-type tumors. Conversely, wild-type tumors
pieces failed to grow in the p190B-deficient stroma, suggest-
ing that loss of p190B. These data are consistent with recent
studies in which siRNA knockdown of p190B inhibited capil-
lary tube formation in Matrigel by human umbilical vein
endothelial cells [35]. Interestingly, these transplantation
experiments revealed a decreased time to tumor burden in the
p190B+/-Neu transplant tumors compared with the p190B+/
+Neu tumors. The mechanism responsible for this difference
remains to be elucidated. One potential explanation, however,
may be that the cells which initiated the p190B+/-Neu tumors
had already acquired significant genetic changes in order to
develop the initial tumor in the absence of one allele of p190B,
which in the presence of wild-type stroma impart a growth
advantage. For example, PAK1/2 activity is elevated in the het-
erozygous tumors, and PAK1 hyperactivation promotes mam-
mary tumor formation in part by activating p38MAPK signaling
and proliferation [25]. Elevated PAK activity may therefore
allow the tumor cells to respond more robustly to proliferative
cues present in the wild-type stroma. Further studies, includ-
ing microarray analysis of the original and transplanted tumors,
as well as transplantation experiments in which p190B+/-Neu
mammary epithelium is introduced into wild-type stroma and is
allowed to go through the stochastic process of tumor forma-
tion, will be required to fully understand the contribution of
p190B in the epithelium to tumor initiation, growth, and pro-
gression.Available online http://breast-cancer-research.com/content/11/4/R61
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Conclusions
Elevated expression of Rho GTPases has been detected in
many types of cancer including breast cancer [36]. RhoA,
RhoB, Rac1/Rac1b, and Cdc42 are overexpressed in breast
tumors, with RhoA expression associated with advanced
stages of the disease [6,37]. RhoC overexpression has been
associated with inflammatory breast cancer and may be
involved in tumor angiogenesis [5,7]. Our studies demonstrate
that p190B, an inhibitor of the Rho GTPases, is required for
Rho/ROK signaling during mammary tumorigenesis and point
to a critical role for p190B in the vasculature during tumor pro-
gression. These studies highlight the importance of investigat-
ing the effects of altered Rho signaling in the context of the in
vivo environment in order to elucidate the role of this signaling
network in breast cancer. The functional role of Rho GTPases
in the different subtypes of human breast cancer remains
understudied, but these studies using mouse models suggest
that this pathway may play an important role in tumor progres-
sion.
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